Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- BUSINESS NEWS IN BRIEF
November 24, 2008
- Wholesale Business Management Seminar
November 24, 2008
- ASKA, Actavis Create Generic Joint Venture Firm in Japan
November 24, 2008
- Santen to Recover Market Share with Tafluprost
November 24, 2008
- DPC Has Increased Use of Generics in over 60 DPC Hospitals: JHA Survey
November 24, 2008
- Kaken: Artz's Sales Up 9.1% Despite NHI Price Cut of 5.8%
November 24, 2008
- Daiichi Sankyo Ties Up with ArQule for Oncology Therapeutics
November 24, 2008
- Kyorin: First Net Loss due to Withdrawal of Gatifloxacin
November 24, 2008
- R&D NEWS IN BRIEF
November 24, 2008
- Mochida: Forecasts for Both Sales and Profits Revised Upward
November 24, 2008
- Chuikyo Will Continue to Review FPMAJ's Drug Pricing System Reform Proposal: Mr Nagano
November 24, 2008
- Kissei: New Products Make Up for Drop in Sales of Cabaser
November 24, 2008
- Kenporen Generally Satisfied with Improvements of Distribution Business Practices
November 24, 2008
- Nippon Shinyaku: Sales Up 14.1% Due to Licensing of NS-304
November 24, 2008
- REGULATORY NEWS IN BRIEF
November 24, 2008
- Seikagaku: Good Domestic Sales Fail to Make Up for Decreases in Exports
November 24, 2008
- Savings of Up to \18 Tril. Possible by Self Med: NRK Report
November 24, 2008
- MEDICAL DEVICE NEWS IN BRIEF
November 24, 2008
- Zeria: Poor Sales of Healthcare Products Depress Overall Performance
November 24, 2008
- Controversies Continue over On-line Sale of Drugs
November 24, 2008
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…